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Abstract
Background:  Systemic vasculitides constitute a heterogeneous group of diseases of
autoimmunological origin characterized by inflammation of blood vessels and antibodies that react
against autoantigens in a process that ultimately affects blood vessel walls. An important number of
these patients present kidney disease. An endeavour of this area of research is the identification of
autoantigens involved in these diseases. Accordingly, we used serum from a patient suffering from
a microscopic polyangiitis, P-ANCA positive, manifesting a clinically atypical renal necrotizing
glomerulonephritis and interstitial nephropathy for the identification of autoantigens; we also
determined the prevalence of corresponding autoantibodies in other vasculitides, diabetic
microangiopathy and in general population.
Methods: The patient's serum was used as a probe for the immunoscreening method SEREX to
screen a human brain cDNA expression library.
Results: Four positive clones were isolated and sequenced. Clones Jos002 code for protein
HDAC5, Jos014 for TFC4, Jos107 for RTF1, and Jos313 for POLDIP3 polymerase. The four
proteins are of nuclear localization. None of them had been reported as autoantigen. Recombinant
proteins were synthesised and checked as antigens by western blot with different sera from
controls and patients affected with other vasculitides and diabetic microangiopathy as well. Only
the serum from the patient origin of this study recognized all recombinant proteins.
Conclusion: We identify four nuclear proteins, HDAC5, TFC4, RTF1 and POLDIP3 polymerase
as new autoantigens that could be used as markers in the diagnosis of subfamilies in immune
diseases, although we cannot determine the role of these proteins in the aetiopathogenic process.
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Background
Systemic vasculitides constitute a heterogeneous group of
diseases characterized by inflammation of blood vessels.
Most of them are of autoimmune origin in which circulat-
ing antibodies are generated against autoantigenic pro-
teins of the patient [1]. Classification of the disease is
mandatory, by the size of the affected vessel, for the
assessment of prognosis and the institution of treatment.
The clinical presentation of vasculitis depends on the ves-
sels involved. An important group includes alteration of
kidney micro vessels in form of glomerulonephritis [2].
Spite of the broad amount of cases and the attributable
pathogenesis of the disease to self-antigens, very few
autoantigens related to this group of diseases have been
found and described [3,4].
In the present work we have studied the immunoreactivity
of the serum of a patient under no treatment, suffering
from a vasculitis characterized by segmental and focal
necrotizing glomerulonephritis with no immune depos-
its. We have identified four nuclear proteins that previ-
ously were unknown as autoantigens and that could be
involved in the biological development of this vasculitis
in which the presence of auto-antibodies is a dominant
feature. We have used an immuno-screening method so
called SEREX (serological identification of antigens by
recombinant expression cloning). SEREX was initially
employed to characterize tumour-expressed antigens elic-
iting an immune response in patients. This method, basi-
cally, consists of screening cDNA expression libraries with
the selected serum to obtain purified clones to subsequent
identification [5].
Methods
Patient data and Sera selection
The serum, taken at the time of biopsy, used as probe for
the screening was obtained from a male patient 18 years
old suffering from a microvasculitis diagnosed as MPA-
microscopic polyangiitis with renal affection typed as
focal-segmental necrotizing glomerulonephritis. P-ANCA
positive and reactivity against MPO, C-ANCA was nega-
tive, serum was not reactive against PR3, ANA negative,
and C3- and C-4 complement fractions were always
within normal levels. Creatinine clearance at that stage
was 37 ml/min. Diagnostic was qualified as "clinically
atypical renal vasculitis". C-ANCA and MPO reactivity
were negative after treatment with cyclophosphamide
plus corticosteroids. Spite of the rapidly progressive
glomerulonephritis, 6 years later, the patient still keeps a
renal function of about 40 ml/min. For this study, eight-
een healthy people (laboratory personnel), ten patients
suffering from vasculitides and five diabetic microangiop-
athy with renal glomerular affection were selected as con-
trols. Control vasculitides were CSS, WG, PAN, SLE and
other MPA. Neither patients nor controls were undergoing
any pharmacological treatment at the time blood samples
were taken. In our study, sera from patients with vasculitis
were used as positive controls for ANCAs, and samples
from healthy people were assayed as negative ones. All of
them were informed of the study and study was approved
by the Ethical Committee of the Hospital Universitario
Nuestra Señora de Candelaria, Tenerife, Spain, in compli-
ance with the Helsinki Declaration. Psychological evalua-
tion described the personality of the patient as 'slightly
immature for the age'.
Methods used are described in Sambrook et al, 1989 [6],
briefly as follows.
Immunoscreening
A human brain cDNA expression library (Clontech, CA,
USA) was used to perform the screening. The serum used
as probe was diluted to a final concentration of 1:2000 in
TBS, 0.05% Tween 20©, 3% bovine serum albumin and
0.01% sodium azide.
Sequencing and alignments
DNA sequencing was performed by Sistemas Genómicos
(Valencia, Spain). Clones for sequencing were prepared
with the Qiaprep kit (Qiagen, Germany) following the
instructions of the manufacturer. Sequence alignment
with those in the GenBank, EMBL, DDBJ and PDB data-
bases were performed using the BLASTN and BLASTX
algorithms [8].
Recombinant protein production
Selected cDNA clones (Jos002, 014, 107 and 313) were
cloned in expression vectors pRSET A/B (Novagen, Ger-
many). Expression of the recombinant proteins was
allowed to proceed for 3–4 hours post-induction with 1
mM final concentration of IPTG in the E. coli BL21 (DE3)
pLys-S bacterial culture. The bacterial cells were harvested,
sonicated, and the fusion proteins were purified using kit
Mg MagneHis™ Protein Purification System (Cat. #V8500,
Promega).
Western-blot
The recombinant proteins were electrophoresed on a
denaturing 15% polyacrylamide gel and transferred to
Immobilon™-P membranes (Millipore, MA, USA) by elec-
troblotting. After blocking the filters with PBS, 0.1%
Tween 20©, 5% dry milk, were incubated with 1:5000 sera
from patients and controls in PBS, 0.1% Tween 20©, 0.5%
dry milk for one hour. After washing, the blot was incu-
bated with secondary goat anti-human IgG conjugated to
horseradish peroxidase (Boehringer Mannheim, IN, USA)
diluted 1:10 000 in PBS, 0.1% Tween 20©, 0.5% dry milk
for 30 minutes. Detection was performed using ECL plus
(Amersham Pharmacia Biotech, England) reagents
according to the manufacturer's instructions. A differentJournal of Autoimmune Diseases 2008, 5:3 http://www.jautoimdis.com/content/5/1/3
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western blot membrane containing the four recombinant
proteins was used for each patient or control.
Expression patterns
Expression of the four autoantigens in different tissues
was analyzed by Virtual Northern blot in the Genomics
Institute of the Novartis Research Foundation web [7].
Results and discussion
Cloning, denomination and expression of auto antigenic 
proteins
We performed a SEREX immunological screening using as
probe the serum of a patient suffering from focal-segmen-
tal glomerulonephritis. First name of this patient is Josué,
based on this fact we decide to name clones 'pJos' and cor-
respondent proteins 'Jos' followed by the number of the
clone. Trough this method, we obtained four plaque pure
clones which cDNAs were subcloned in pBluescript KS
(plasmids pJos002, 014, 107 and 313) and sequenced.
Aligning of sequences with those in GenBank, EMBL,
DDBJ and PDB databases was done using the BLASTX and
BLASTN algorithms [8].
Jos002
This sequence is 100% homologous to the human
HDAC5 (histone deacetylase 5) and ortologue to Hda1p of
Saccharomyces cerevisiae. Histone acetilation and deacetila-
tion is part of a fundamental mechanism of gene expres-
sion control. HDAC5 belongs to HDACs IIa group which
plays an important role by controling interactions among
DNA and transcription factors and have implicated as glo-
bal regulators of gene expression during cell differentia-
tion and development [9]. McKinsey et al, suggest a role as
signal-responsive regulators of antigen presentation to
class II histone deacetylases when associated with
ankyrin-repeat proteins [10].
Jos014
This sequence is homologous 100% to human FLJ16014
fis (full insert sequence) cDNA which is highly homologous
to TFC4 (Transcription factor 4, isoform b). Presents a helix-
turn-helix motif that binds to E-box (Ephrussi), 'CAN-
NTG'. This sequence is among the first domains described
for immunoglobulin stimulators. TCF4 is mostly
expressed in immature lymphocytes B and possesses sev-
eral mRNA species, although isoform b is the only one
complete. Very recently has been reported that Tcf4 pro-
tein is involved in differentiation of neuronal progenitors
and that haploinsufficiency of TCF4 causes the Pitt-Hop-
kins mental retardation syndrome [11]. This fact could be
related to the mental retardation of the patient subject in
this study, although in this patient Pitt-Hopkins syn-
drome was discarded.
Jos107
is homologous 100% to human RTF1/Rtf1 cDNA, Paf1/
RNA polymerase II complex component [12], also called
KIAA0252 and GTL7. RTF1 codes for a protein involved in
regulation of transcription, chromatin structure and his-
tone metilation in Drosophila through several independ-
ent functional domains [13-15]. Presents a PSSMs
domain (Plus-3) 90 residues long, frequently associated to
the pfam02213 domain, possess three residues with posi-
tive charge which is the origin of its denomination and
that could be responsible for DNA binding.
pJos313
This sequence is homologous to human POLDIP3
polymerase (DNA-directed), delta interacting protein 3,
also called SKAR, PDIP46 and KIAA1649. POLDIP3 binds
to DNA and RNA during replication process, is a specific
target of S6 kinase 1, interacts with p50 subunit of DNA
polymerase delta, possess duplex DNA-unwinding and
ATPase activities and regulates cell growth [16-18].
The four autoantigenic proteins reported are of nuclear
localization.
Sizes of the above mentioned clones, genes that encode
them, chromosome in which they are and data of the pro-
teins are shown in Table 1.
The expression pattern of these genes in human was stud-
ied by a virtual Northern-blot analysis. Figure 1 shows the
searching results. HDAC5 reaches a higher expression
level in placenta, brain (both, adult and foetal), and heart.
Table 1: Some characteristics of genes and encoded proteins corresponding to isolated clones.
CLON SIZE GENE CHROMOSOME ENCODED PROTEIN N° OF AA MW (kDa)
Jos002 1000 pb HDAC5 17q21 HDAC5
Human Histone deacetylase 5
1122 122
Jos014 719 pb TFC4 18q21.1 TFC4
Transcription factor 4 isoform b
667 71.3
Jos107 800 pb RTF1 15q.15.1 RTF1
Paf/RNA polymerase II complex component
429 49.1
Jos313 1000 pb POLDIP3 22q13.2 POLDIP3
DNA polymerase delta interacting protein 3
421 46.1Journal of Autoimmune Diseases 2008, 5:3 http://www.jautoimdis.com/content/5/1/3
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TCF4 is expressed at a medium level in most tissues with
the exception of PB-BDCA4+ (dendritic cell line) with a
ten fold of the average expression level. RTF1 expression
pattern shows the highest level in BM-CD34+ cells and
medium in endothelial tissue BMCD105 and PB-BDCA4+
and T CD4+ cell lines. POLDIP3 is the most evenly distrib-
uted protein among tissues, spleen is the predominant.
The recombinant proteins
Recombinant proteins sequences are shown in figure 2.
Recombinant protein Jos002 is formed by 355 residues
with a mw of 38 kDa. Amino acids in bold characters
(thirty-six) correspond to expressed part of cloning vector
pRSET-B, underlined amino acids (twenty-two) to λg11
phage. Sequence Jos002 matches to HDAC5 C-terminus
(from I826 to L1122). Figure 3 shows two smaller bands for
this recombinant protein as result that E. coli, during the
biosynthetic process splits this protein into two peptides
of about 18 and 20 kDa.
Recombinant protein Jos014 is formed by 246 residues
with a mw of 32 kDa. Amino acids in bold characters
(thirty-eight) correspond to expressed part of cloning vec-
tor pRSET-A, underlined amino acids (nineteen) to λg11
phage. Sequence Jos014 matches to TFC4 N-terminus
(from M1 to A189).
Recombinant protein Jos107 is formed by 324 residues
with a mw of 36 kDa. Amino acids in bold characters
(thirty-eight) correspond to expressed part of cloning vec-
tor pRSET-B, underlined amino acids (twenty-two) corre-
Virtual northern blot of genes coding for autoantigens reported in this study Figure 1
Virtual northern blot of genes coding for autoantigens reported in this study. Horizontal axis, tissues and cell lines; 
vertical axis, expression level of the given gene in arbitrary units of intensity.Journal of Autoimmune Diseases 2008, 5:3 http://www.jautoimdis.com/content/5/1/3
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spond to expressed part of λgt11 phage. Sequence Jos107
matches to Rtf1 (Paf1/RNA polymerase II complex com-
ponent) C-terminus (T167 to I429).
Recombinant protein Jos313 is formed by 320 residues
with a mw of 35 kDa. Amino acids in bold characters
(forty-five) correspond to expressed part of cloning vector
pRSET-A. Sequence Jos313 matches to Poldip3 (DNA
polymerase delta interacting protein 3) (V30 to G304). Pro-
tein Jos313 is degraded by E. coli during the biosynthesis
process into a non determined number of peptides, as
shown in figure 3.
Immunoreactivity of recombinant proteins the against 
patient's serum
Immunoreactivity of recombinant proteins described pre-
viously against patient's serum was checked by western-
blot. Serum was diluted to 1:5000. Figure 3, panel B
shows how these proteins are clearly recognized by the
serum. As negative control in order to check serum cross-
reactivity against usual E. coli products, the insert of clone
Jos014 was expressed in the reverse orientation; as
expected, an 8 kDa peptide was produced that was not rec-
ognized by any serum (data not shown).
Prevalence and autoantibodies detection in sera from 
patients suffering from vasculitides
Eighteen sera from apparently healthy people with no
familial history of rheumatic diseases were tested by west-
ern blot for reactivity against all four recombinant pro-
teins; none of them gave a positive signal, figure 4, panel
B. This fact points out that none of them is a prevalent
antigen. Sera from ten patients suffering of vasculitides (3
SLE, 4PAN, 1 WG, 1 CSS and 1 PMA) were also tested for
Primary sequence of recombinant proteins used as antigens to check autoantibodies Figure 2
Primary sequence of recombinant proteins used as antigens to check autoantibodies. Amino acids in bold charac-
ters correspond to expressed part of cloning vector pRSET-B, underlined amino acids to λg11 phage.
  FUSION PROTEIN SEQUENCE 
PJos002
355aa
38kDa
MRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDRWGSIRARDLQWRRLLEPXSIXGGFAII
RPPGHHAEESTAMGFCFFNSVAITAKLLQQKLNVGKVLIVDWDIHHGNGTQQAFYNDPSV
LYISLHRYDNGNFFPGSGAPEEVGGGPGVGYNVNVAWTGGVDPPIGDVEYLTAFRTVVMP
IAHEFSPDVVLVSAGFDAVEGHLSPLGGYSVTARCFGHLTRQLMTLAGGRVVLALEGGHD
LTAICDASEACVSALLSVELQPLDEAVLQQKPNINAVATLEKVIEIQSKHWSCVQKFAAG
LGRSLREAQAGETEEAETVSAMALLSVGAEQAQAAAAREHSPRPAEEPMEQEPAL 
PJos014
246aa
32 kDa 
MRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDPSSRSAGRCTESPFSRAGGLCDFAKMHH
QQRMAALGTDKELSDLLDFSAMFSPPVSSGKNGPTSLASGHFTGSNVEDRSSSGSWGNGG
HPSPSRNYGDGTPYDHMTSRDLGSHDNLSPPFVNSRIQSKTERGSYSSYGRESNLQGCHQ
QSLLGGDMDMGNPGTLSPTKPGSQYYQYSSNNPRRRPLHSSAMEVQTKKVRKVPPGLPSS
VYAPSA… 
pJOS107
324aa
36kDa
MRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDRWGSELEVDGIDKLDGDDSWSPSVSAEF
TESEFMKWKEAMFSAGMQLPTLDEINKKELSIKEALNYKFNDQDIEEIVKEKERFRKAPP
NYAMKKTQLLKEKAMAEDLGDQDKAKQIQDQLNELEERAEALDRQRTKNISAISYINQRN
REWNIVESEKALVAWKSHLENPPDGFPFTRRQCKPTIVSNSRDPAVQAAILAQLNAKYGS
GVLPDAPKEMSKGQGKDKDLNSKSASDLSEDLFKVHDFDVKIDLQVPSSESKALAITSKA
PPAKDGAPRRSLNLEDYKKRRGLI
pJOS313
320aa
35kDa
MRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDPSSRSAAGTMEFRVRSRVGIQQGLLSQS
TRTATFQQRFDARQKIGLSDARLKLGVKDAREKLLQKDARFLIKGKVQDAREMLNSRKQQ
TTVPQKPRQVADAREKISLKRSSPAAFINPPIVTVTPALKLTKTIQVPQQKAMAPLHPHP
AGMRINVVNNHQAKQNLYDLDEDDDGIASVPTKQMKFAASGGFLHHMAGLSSSKLSMSKA
LPLTKVVQNDAYTAPALPSSIRTKALTNMSRTLVNKEEPPKELPAAEPVLSPLEGTKMTV
NNLHPRVTEEDIVELFCVCGJournal of Autoimmune Diseases 2008, 5:3 http://www.jautoimdis.com/content/5/1/3
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reactivity by western blot against the recombinant pro-
teins. Recombinant protein Jos002, a part of HDAC5, was
recognized only for serum from one PAN patient (Figure
4, panel F), recombinant proteins Jos014, 107 and 313,
were recognized in a scatter manner and with lower inten-
sity than control (Josue's serum, Figure 4, panel A) by sera
from some patients, as shown in figure 4, panels C to L.
Prevalence of autoantibodies in renal glomerular diabetic 
microangiopathy
We checked the prevalence of autoantibodies against
these proteins in patients suffering from a diabetic micro-
angiopathy. None of these patients were positive for MPO
or any ANCA. Results are shown in figure 4 panels M to Q.
None of the sera reacted against proteins Jos002, two sera
recognized Jos313 (Fig. 4, panels M and N), three out of
five reacted against Jos107 and Jos014 (Fig. 4, panels M,
O and P), sera from one patient did not react against any
recombinant protein (Fig. 4, panel Q). These results might
be indicative of cell destruction and autoantigens release
and subsequent autoantibodies production. Whether the
origin of antigens of broken cell nuclei is microvascular
endothelial cells within a concurrent inflammatory proc-
ess or any other affected cell remains to be elucidated.
Given the amount of cases studied there is no point of
doing any statistical analysis, however, we can conclude
that: a) none of the antibodies is prevalent in general pop-
ulation, b) autoantibodies against HDAC5 have low prev-
alence and c) autoantibodies against RTF1 and POLDIP3
are prevalent in both vasculitides and diabetic angiopa-
thy.
Autoantibodies and pathogenesis of nephro-glomerular 
vasculitis
We tried to reproduce some signs of this vasculitis, as
glomerulonephritis or proteinury, by immunizing a series
of mice (CB1/swiss species) with the recombinant pro-
teins, either by injecting only one protein per mice or the
four proteins together. Experimental procedures in mice
were in accordance with the guidelines of the Animal Care
Advisory Committee of the University of La Laguna. Sera
from all animals were previously tested by western blots
for possible auto antibodies prevalence against the anti-
gens to test and proteins in urine; none of them gave a
positive result. Six groups of four mice 5–6 weeks old each
were made, four groups were immunized with 20 μg of
the correspondent recombinant protein, the fifth with 10
μg of each protein, the sixth group, control, injected only
with the vehicle and complete or incomplete Freund's
adjuvant (complete day 0 and incomplete rest of immuni-
zations). Mice were placed in metabolic cases and injected
at days 0, 10, 20, 40, 56, 70 and 84. Urea, creatinine, Ca2+,
Na+, K+, Cl-, phosphates and total proteins in both, serum
and urine, were determined previous to injections. No sig-
nificant changes from controls were found in any mice at
any point of the study. Mice were sacrificed at day 90, sera
were collected and kidneys saved for histological studies.
(A) Recombinant proteins stained by coomassie blue Figure 3
(A) Recombinant proteins stained by coomassie blue. Note the split peptide of Jos002 and multiple peptides in Jos313 
(B) Western blot of recombinant proteins probed with serum from the patient origin of this study.Journal of Autoimmune Diseases 2008, 5:3 http://www.jautoimdis.com/content/5/1/3
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Histological studies showed neither glomerular, nor tubu-
lar, nor interstitial nor minimal changes.
Western blots with sera from immunized mice showed
reactivity against their correspondent recombinant pro-
teins at titles as high as 1:5000. All this data together sug-
gest that although the recombinant proteins elicited a
good level of antibodies, these were not able to produce
any damage, either morphological or functional, to the
kidney.
To our knowledge, elegant and sophisticated experiments
headed by Jennette and Falk [19,20] show that Rag2(-/-)
mice injected intravenously with splenocytes from MPO
immunized Mpo(-/-) knockout mice after immunisation
with MPO protein has been shown to develop a glomeru-
lonephritis, and systemic necrotizing vasculitis similar to
humans.
Conclusion
Autoantibodies against four proteins, HDAC5, TFC4,
RTF1 and POLDIP3, observed in this study further con-
firms the autoimmune reactions in vasculitides and may
provide new inroads into elucidating the immunopatho-
genesis of the disease. Most antibodies related to autoim-
mune diseases are considered as markers rather than
etiopathogenic agents and, generally, are used as diagnos-
tic tools associated to a determined disease based on sta-
Autoantibodies detection in controls and in sera from patients suffering of vasculitides Figure 4
Autoantibodies detection in controls and in sera from patients suffering of vasculitides. Panel A shows a western 
blot probed with the serum from the patient subject of the study and panel B the western blot probed with serum from a rep-
resentative healthy control. Panels C to H show western blot analysis of autoantibodies in several vasculitis patient's sera, suf-
fering SLE (C to E), PAN (F to H and L), MPA (I), WG (J) and CSS (K). Panels M to Q show western blot analysis of 
autoantibodies of five patients suffering form diabetic microangiopathy. Specific molecular mass for each recombinant protein 
are shown between panels A and C, B and F, I and J and N and O.Journal of Autoimmune Diseases 2008, 5:3 http://www.jautoimdis.com/content/5/1/3
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tistics or epidemiological correlations. In the present
study, additional assays to prove the involvement of the
various autoantibodies in the pathogenesis and reproduce
the disease in mice, however, did not support the hypoth-
esis, either because the experimental model was devel-
oped in different species or because damaging antibodies
were not generated or some epitopes were missing in the
recombinant proteins. A long time study (years) reporting
a larger amount of cases will give us the interest of autoan-
tigens described in this article as predictive markers in vas-
culitides.
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